After laying off 100 Amylin employees shortly after the merger, Bristol-Myers now plans to try to relocate some 100-125 remaining workers to its other facilities in such tax-free meccas as New Jersey, Connecticut, Belgium, and Japan.
Fate, however, will be less kind to the other 300 Amylin personnel, whom Egenolf described as filling “commercial, R&D, manufacturing, corporate staff and administrative roles,” to say nothing of the 266,000 soon-to-be vacant square feet flooding an already depressed commercial real estate market.
Sunday, April 21, 2013
California’s doldrums continue
Well written article on the business climate in CA.